Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, BioTrove, Bruker, Arizona Personalized Medicine Initiative, GenoLogics

Agilent, BioTrove in Co-Marketing Agreement
Agilent and BioTrove this week reached an agreement to co-market Agilent’s 6410 Triple-Quadrupole MS with BioTrove’s RapidFire high-throughput sample preparation systems.
Terms of the agreement were not disclosed.
The deal allows for integration of “the fastest sample preparation system on the market” with the 6410, said Guenter Nill, general manager of Agilent’s pharmaceutical and biotech market, and should benefit pharmaceutical companies “that want to spend less time and money discovering new leads and developing more effective medicines.”

Proteomics Tools in Bruker’s New Beijing Facility
Bruker BioSciences this week announced the official opening of an application, demonstration, and customer training facility in Beijing. Instruments in the facility include several with proteomics applications: the Bruker Daltonics autoflex III Smartbeam MALDI-TOF/TOF MS; the Daltonics HCTultra PTM discovery system ESI-ion trap with electron transfer dissociation capability; and a Daltonics micrOTOF-Q ESI-Q-q-TOF system.

Proteomics Facility to be Created as Part of Personalized Dx Effort
A high-throughput proteomics production facility will be established as part of a $45 million initiative in Arizona to develop personalized molecular diagnostics. The effort is being funded by the Virginia G. Piper Charitable Trust, which is committing $35 million, and the Flinn Foundation which will contribute $10 million.
Lee Hartwell, director of the Fred Hutchinson Cancer Research Center will lead the effort. The cornerstone of the Partnership for Personalized Medicine will be the creation of the Virginia G. Piper Center for Personalized Diagnostics.
The proteomics facility will tap into expertise at Arizona State University’s Translational Genomics Research Institute and the Biodesign Institute in robotics, protein analysis, and computing, to develop new proteins for the development of diagnostic tests for cancer and other illnesses.

GenoLogics Partners with London Genetics
GenoLogics this week announced a partnership with London Genetics to provide expertise in informatics infrastructure as London Genetics tries to build a research network of scientists. GenoLogics Proteus and Geneus platforms will be used by potential London Genetics consortia members where appropriate.
The two companies will also identify collaborative projects and grant funding opportunites. London Genetics facilitates and manages partnerships between the healthcare industry and biomedical facilities in London.
Terms of the agreement were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.